MedTrace Logo

BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma

NCT06414434 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-04-30

No results posted yet for this study

Summary

This study is testing two different doses of BTX-A51 to determine if it is safe and tolerable in participants with liposarcoma with MDM2 amplification, myxoid liposarcoma, and CIC-rearranged sarcoma.

The name of the study drug used in this research study is:

-BTX-A51 (a type of kinase inhibitor)

Conditions

  • Liposarcoma
  • Recurrent Liposarcoma
  • Metastatic Liposarcoma
  • Unresectable Liposarcoma
  • MDM2 Gene Amplification
  • Myxoid Liposarcoma
  • CIC-Rearranged Sarcoma

Interventions

DRUG

BTX-A51

Multi-kinase inhibitor, 1.0 mg, 2.0 mg, and 7.0 mg immediate-release capsules, taken orally per protocol.

Sponsors & Collaborators

  • Edgewood Oncology Inc.

    collaborator INDUSTRY

  • Michael Wagner, MD

    lead OTHER

Principal Investigators

  • Michael Wagner, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-30
Primary Completion
2026-06-01
Completion
2027-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06414434 on ClinicalTrials.gov